Aridis Pharmaceuticals, Inc. signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pharmaceuticals for the prevention and treatment of infectious diseases with a focus on unmet needs in global health and biodefense. Aridis and MappBio have committed to work exclusively with each other to expeditiously complete definitive licensing agreements MappBio's pan-Ebola and pan-Marburg mAb programs are currently in Phase 1 clinical studies and both products have shown best-in-class protection against live virus challenges in non-human primates. The Strategic National Stockpile is a federally funded program that acquires, stores, and distributes medical countermeasures in the event of a public health emergency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0614 USD | -12.29% | +4.07% | -12.41% |
1st Jan change | Capi. | |
---|---|---|
-12.41% | 2.94M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+2.07% | 22.39B | |
-10.79% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical